Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.067 AUD | +3.08% | -9.46% | -5.63% |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Feb. 26 | Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 5.43M 3.52M | Sales 2023 | 6.01M 3.9M | Capitalization | 12.57M 8.15M |
---|---|---|---|---|---|
Net income 2022 | -18M -11.68M | Net income 2023 | -15M -9.73M | EV / Sales 2022 | 7.95 x |
Net cash position 2022 | 13.85M 8.99M | Net cash position 2023 | 3.01M 1.95M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
1 day | +3.08% | ||
1 week | -9.46% | ||
Current month | -17.28% | ||
1 month | -14.10% | ||
3 months | -5.63% | ||
6 months | +59.52% | ||
Current year | -5.63% |
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.067 | +3.08% | 37 671 |
24-03-27 | 0.065 | +6.56% | 28,433 |
24-03-26 | 0.061 | -6.15% | 205,083 |
24-03-25 | 0.065 | -8.45% | 488,610 |
24-03-22 | 0.071 | -4.05% | 327,691 |
Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-5.63% | 12.39M | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.30% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |